ERBB2 and breast cancer: Based on the recommended phase II dose of burparlisib as 100 mg/day in combination with 2 mg/kg weekly tratuzumab from phase IB, 50 patients with HER2+ locally advanced breast cancer resistant to trastuzumab-based treatment were treated with this therapeutic regimen (Pistilli et al., 2018).